Every reason to discontinue lithium

Lithium as a gold standard therapy for bipolar disorder is well known to have a number of medical comorbidities that impact renal, parathyroid, and thyroid function. Despite these medical comorbidities, there remains a group of lithium-responsive lithium-treated patients who have maintained mood sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgado, Manuel E Fuentes, Sutor, Bruce, Albright, Robert C, Frye, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477477/
https://www.ncbi.nlm.nih.gov/pubmed/26092398
http://dx.doi.org/10.1186/s40345-014-0012-y
_version_ 1782377768804155392
author Salgado, Manuel E Fuentes
Sutor, Bruce
Albright, Robert C
Frye, Mark A
author_facet Salgado, Manuel E Fuentes
Sutor, Bruce
Albright, Robert C
Frye, Mark A
author_sort Salgado, Manuel E Fuentes
collection PubMed
description Lithium as a gold standard therapy for bipolar disorder is well known to have a number of medical comorbidities that impact renal, parathyroid, and thyroid function. Despite these medical comorbidities, there remains a group of lithium-responsive lithium-treated patients who have maintained mood stability for decades. The risk/benefit ratio of end organ toxicity/mood stability must be evaluated in each individual case.
format Online
Article
Text
id pubmed-4477477
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-44774772015-06-24 Every reason to discontinue lithium Salgado, Manuel E Fuentes Sutor, Bruce Albright, Robert C Frye, Mark A Int J Bipolar Disord Letter to the Editor Lithium as a gold standard therapy for bipolar disorder is well known to have a number of medical comorbidities that impact renal, parathyroid, and thyroid function. Despite these medical comorbidities, there remains a group of lithium-responsive lithium-treated patients who have maintained mood stability for decades. The risk/benefit ratio of end organ toxicity/mood stability must be evaluated in each individual case. Springer Berlin Heidelberg 2014-11-08 /pmc/articles/PMC4477477/ /pubmed/26092398 http://dx.doi.org/10.1186/s40345-014-0012-y Text en © Salgado et al.; licensee Springer. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Letter to the Editor
Salgado, Manuel E Fuentes
Sutor, Bruce
Albright, Robert C
Frye, Mark A
Every reason to discontinue lithium
title Every reason to discontinue lithium
title_full Every reason to discontinue lithium
title_fullStr Every reason to discontinue lithium
title_full_unstemmed Every reason to discontinue lithium
title_short Every reason to discontinue lithium
title_sort every reason to discontinue lithium
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477477/
https://www.ncbi.nlm.nih.gov/pubmed/26092398
http://dx.doi.org/10.1186/s40345-014-0012-y
work_keys_str_mv AT salgadomanuelefuentes everyreasontodiscontinuelithium
AT sutorbruce everyreasontodiscontinuelithium
AT albrightrobertc everyreasontodiscontinuelithium
AT fryemarka everyreasontodiscontinuelithium

Ejemplares similares